Scancell Holdings plc (SCNLF)
| Market Cap | 137.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.36M |
| Shares Out | n/a |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Average Volume | 6,732 |
| Open | 0.1698 |
| Previous Close | 0.1400 |
| Day's Range | 0.1698 - 0.1698 |
| 52-Week Range | 0.0980 - 0.2335 |
| Beta | -0.09 |
| RSI | 48.80 |
| Earnings Date | May 2, 2025 |
About Scancell Holdings
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clin... [Read more]
News
PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet and Scancell agreement builds on PharmaJet's strategy to be the best-in-class delivery system for novel DNA and RNA cancer immunotherapies.
PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free
GOLDEN, Colo.--(BUSINESS WIRE)--Positive data announced for first stage of Phase 2 trial for advanced melanoma DNA vaccine delivered by the PharmaJet Stratis needle-free system.